PHOENIXVILLE, PA — Facet Life Sciences has entered a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and regulatory approval of next-generation radiopharmaceutical therapies for cancer patients.
As part of the collaboration, Facet is now featured on TheranosticTrials.Org®, XCancer’s global platform designed to connect researchers, clinicians, sponsors, and advocates. The platform aims to expand access to clinical trials, foster collaboration, and advance the reach of innovative cancer treatments.
The partnership brings together Facet’s regulatory and development expertise in diagnostic and therapeutic radiopharmaceuticals with XCancer’s extensive theranostic trial network. The two organizations plan to streamline regulatory pathways and clinical activation processes, enabling faster delivery of precision oncology treatments to patients worldwide.
“At Facet, our mission has always included bringing diagnostic and radiopharmaceutical therapies to patients faster and more efficiently,” said Dr. Lisa Jenkins VanLuvanee, chief operating officer of Facet Life Sciences. “By partnering with XCancer and TheranosticTrials.Org, we are combining our regulatory and oncology expertise with their groundbreaking clinical research capabilities. This collaboration positions us to accelerate the advancement of theranostic therapies and expand patient access to precision medicine.”
XCancer’s founder and CEO, Dr. Luke Nordquist, said the partnership aligns perfectly with his organization’s mission to advance personalized care. “Facet’s proven regulatory and strategic development expertise complements XCancer’s mission perfectly,” he said. “Together, we are building an ecosystem that removes barriers for sponsors, accelerates clinical trial activation, and brings life-changing radiopharmaceutical therapies to patients who need them most.”
The alliance underscores a growing trend in oncology—integrating diagnostic imaging with targeted therapy, known as theranostics. By merging scientific innovation with regulatory efficiency, Facet and XCancer aim to help the next wave of radiopharmaceutical therapies reach patients sooner and with greater precision.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.